Propylpyrazoletriol

Propylpyrazoletriol (PPT) is a synthetic, nonsteroidal agonist of ERα with 400-fold selectivity over ERβ[1] that is used widely in scientific research to study the function of ERα.[2][3][4] Though originally thought to be highly selective for ERα, PPT has subsequently been found to also act as an agonist of the GPER (GPR30).[5]

Propylpyrazoletriol
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H22N2O3
Molar mass386.451 g·mol−1
3D model (JSmol)

See also

References

  1. Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 50–. ISBN 978-3-527-62330-3.
  2. Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction: Two-Volume Set. Academic Press. pp. 2311–. ISBN 978-0-12-397769-4.
  3. Cytoplasmic and Nuclear Receptors—Advances in Research and Application: 2012 Edition. ScholarlyEditions. 26 December 2012. pp. 220–. ISBN 978-1-4649-9741-9.
  4. Synthesis of Non-steroidal Estrogen Receptor Proteolysis Targeting Chimeric Molecules (PROTACS). 2008. pp. 11–. ISBN 978-0-549-90990-3.
  5. Prossnitz ER, Barton M (May 2014). "Estrogen biology: new insights into GPER function and clinical opportunities". Molecular and Cellular Endocrinology. 389 (1–2): 71–83. doi:10.1016/j.mce.2014.02.002. PMC 4040308. PMID 24530924.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.